1.Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups
Stefano GREGGI ; Francesca FALCONE ; Giovanni D. ALETTI ; Marco CASCELLA ; Francesca BIFULCO ; Nicoletta COLOMBO ; Sandro PIGNATA
Journal of Gynecologic Oncology 2022;33(5):e60-
Objective:
The European Society of Gynaecological Oncology (ESGO)-quality indicators (QIs) for advanced ovarian cancer (AOC) have been assessed only by few Italian centers, and data are not available on the proportion of centers reaching the score considered for a satisfactory surgical management. There is great consensus that the Enhanced Recovery After Surgery (ERAS) approach is beneficial, but there is paucity of data concerning its application in AOC. This survey was aimed at gathering detailed information on perioperative management of AOC patients within MITO-MaNGO Groups.
Methods:
A 66-item questionnaire, covering ESGO-QIs for AOC and ERAS items, was sent to MITO/MaNGO centers reporting to operate >20 AOC/year.
Results:
Thirty/34 questionnaires were analyzed. The median ESGO-QIs score was 31.5, with 50% of centers resulting with a score ≥32 which provides satisfactory surgical management. The rates of concordance with ERAS guidelines were 46.6%, 74.1%, and 60.7%, respectively, for pre-operative, intra-operative, and post-operative items. The proportion of overall agreement was 61.3%, and with strong recommendations was 63.1%. Pre-operative diet, fasting/bowel preparation, correction of anaemia, post-operative feeding and early mobilization were the most controversial. A significant positive correlation was found between ESGO-QIs score and adherence to ERAS recommendations.
Conclusion
This survey reveals a satisfactory surgical management in only half of the centers, and an at least sufficient adherence to ERAS recommendations. Higher the ESGO-QIs score stronger the adherence to ERAS recommendations, underlining the correlations between case volume, appropriate peri-operative management and quality of surgery. The present study is a first step to build a structured platform for harmonization within MITO-MaNGO networks.
2.Extracorporeal Shock Wave Therapy in Peyronie's Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study
Marina DI MAURO ; Giorgio Ivan RUSSO ; Pier Andrea DELLA CAMERA ; Fabrizio DI MAIDA ; Gianmartin CITO ; Nicola MONDAINI ; Marco CAPECE ; Marco FALCONE ; Francesco SESSA ; Andrea MARI ; Riccardo CAMPI ; Carlotta SABINI ; Sergio SERNI ; Mauro GACCI ; Andrea MINERVINI ; Marco CARINI ; Sebastiano CIMINO ; Girolamo MORELLI ; Andrea COCCI
The World Journal of Men's Health 2019;37(3):339-346
PURPOSE: In this study, we aimed to determine the role of extracorporeal shockwave therapy (ESWT) in the management of Peyronie's disease (PD). MATERIALS AND METHODS: A total of 325 patients suffering from PD were enrolled in this single-arm clinical study. All patients were received ESWT using a schedule of 1 treatment/wk. Penile curvature was measured by a goniometer after intracavernosal drug-induced erection using Alprostadil. Plaque size was measured with a ruler and sexual function assessed by the international index of erectile function (IIEF)-15 score. Severity of erectile dysfunction was classified as severe (IIEF-15 ≤10), moderate (IIEF-15 between 11 and 16), or mild (IIEF-15 between 17 and 25). Results were evaluated at baseline and 3 months after the treatment. RESULTS: All the patients completed the study protocol. Median age was 59.0 years (55.0–64.0 years). After treatment, the median (interquartile range, IQR) plaque size reduced from 1.78 cm2 (1.43–2.17 cm2) to 1.53 cm2 (1.31–1.96 cm2) (p<0.001); the median (IQR) penile length in erection increased from 13.0 cm (12.0–14.0 cm) to 14 cm (13.0–15.0 cm) (p<0.001) and the median (IQR) penile curvature from 30.4° (22.2°–35.4°) to 25.0° (20.2°–30.4°) (p<0.001). We also observed a decrease in pain assessed by visual analogue scale (7 vs. 3; p<0.001), an improvement in each of the IIEF sub-domains (p<0.001) and an improvement in all three PD questionnaire domains (p<0.001). CONCLUSIONS: Based on our findings, ESWT could be considered a safe and efficient minimally invasive option for the management of the patients suffering from PD.
Alprostadil
;
Appointments and Schedules
;
Clinical Study
;
Erectile Dysfunction
;
Humans
;
Male
;
Observational Study
;
Penile Diseases
;
Penile Induration
;
Shock
;
Treatment Outcome
3.How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
Andrea COCCI ; Fabrizio DI MAIDA ; Giorgio Ivan RUSSO ; Marina DI MAURO ; Gianmartin CITO ; Marco FALCONE ; Andrea MINERVINI ; Giovanni CACCIAMANI ; Riccardo CAMPI ; Andrea MARI ; Francesco SESSA ; Nicola MONDAINI
The World Journal of Men's Health 2020;38(1):78-84
4.Is thyroid nodule location associated with malignancy risk?
Valeria RAMUNDO ; Livia LAMARTINA ; Rosa FALCONE ; Laura CIOTTI ; Cristiano LOMONACO ; Marco BIFFONI ; Laura GIACOMELLI ; Marianna MARANGHI ; Cosimo DURANTE ; Giorgio GRANI
Ultrasonography 2019;38(3):231-235
PURPOSE: Nodules located in the upper pole of the thyroid may carry a greater risk for malignancy than those in the lower pole. We conducted a study to analyze the risk of malignancy of nodules depending on location. METHODS: The records of patients undergoing thyroid-nodule fine-needle aspiration cytology (FNAC) at an academic thyroid cancer unit were prospectively collected. The nodules were considered benign in cases of a benign histology or cytology report, and malignant in cases of malignant histology. Pathological findings were analyzed based on the anatomical location of the nodules, which were also scored according to five ultrasonographic classification systems. RESULTS: Between November 1, 2015 and May 30, 2018, 832 nodules underwent FNAC, of which 557 had a definitive diagnosis. The prevalence of malignancy was not significantly different in the isthmus, right, or left lobe. Among the 227 nodules that had a precise longitudinal location noted (from 219 patients [155 females], aged 56.2±14.0 years), malignancy was more frequent in the middle lobe (13.2%; odds ratio [OR], 9.74; 95% confidence interval [CI], 1.95 to 48.59). This figure was confirmed in multivariate analyses that took into account nodule composition and the Thyroid Imaging, Reporting, and Data System (TIRADS) classification. Using the American College of Radiologists TIRADS, the upper pole location also demonstrated a slightly significant association with malignancy (OR, 6.92; 95% CI, 1.02 to 46.90; P=0.047). CONCLUSION: The risk of thyroid malignancy was found to be significantly higher for mid-lobar nodules. This observation was confirmed when suspicious ultrasonographic features were included in a multivariate model, suggesting that the longitudinal location in the lobe may be a risk factor independently of ultrasonographic appearance.
Biopsy, Fine-Needle
;
Classification
;
Diagnosis
;
Humans
;
Information Systems
;
Multivariate Analysis
;
Odds Ratio
;
Prevalence
;
Prospective Studies
;
Risk Factors
;
Thyroid Gland
;
Thyroid Neoplasms
;
Thyroid Nodule
5.Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
Chiara CREMOLINI ; Carlotta ANTONIOTTI ; Filippo PIETRANTONIO ; Rosa BERENATO ; Marco TAMPELLINI ; Chiara BARATELLI ; Lisa SALVATORE ; Federica MARMORINO ; Beatrice BORELLI ; Federico NICHETTI ; Paolo BIRONZO ; Cristina SONETTO ; Maria DI BARTOLOMEO ; Filippo DE BRAUD ; Fotios LOUPAKIS ; Alfredo FALCONE ; Massimo DI MAIO
Cancer Research and Treatment 2017;49(3):834-845
PURPOSE: The purpose of this study was to evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials investigating the efficacy of targeted agents in the second-line treatment of metastatic colorectal cancer (mCRC). MATERIALS AND METHODS: A systematic search of literature pertaining to randomized phase II and III trials evaluating targeted agents as second-line treatments for mCRC was performed. The strength of the correlation between both PFS and ORR and OS was assessed based on the Pearson's correlation coefficient (R) and the coefficient of determination (R²). RESULTS: Twenty trials, including a total of 7,571 patients, met the search criteria. The median duration of post-progression survival (PPS) was 7.6 months. The median differences between experimental and control arms were 0.65 months (range, –2.4 to 3.4) for the median PFS and 0.7 months (range, –5.8 to 3.9) for the median OS. PFS and ORR showed moderate (R=0.734, R²=0.539, p < 0.001) and poor correlation (R=0.169, R²=0.029, p=0.476) with OS, respectively. No differences between anti-angiogenic agents and other drugs were evident. CONCLUSION: Targeted agents investigated in the second-line treatment of mCRC provided minimal PFS gains translating into modest OS improvements. Considering both the moderate correlation between PFS and OS and the short duration of PPS, the OS should remain the preferred primary endpoint for randomized clinical trials in the second-line treatment of mCRC.
Arm
;
Biomarkers*
;
Colorectal Neoplasms*
;
Disease-Free Survival
;
Humans
;
Molecular Targeted Therapy
;
Translating
6.Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
Chiara CREMOLINI ; Carlotta ANTONIOTTI ; Filippo PIETRANTONIO ; Rosa BERENATO ; Marco TAMPELLINI ; Chiara BARATELLI ; Lisa SALVATORE ; Federica MARMORINO ; Beatrice BORELLI ; Federico NICHETTI ; Paolo BIRONZO ; Cristina SONETTO ; Maria DI BARTOLOMEO ; Filippo DE BRAUD ; Fotios LOUPAKIS ; Alfredo FALCONE ; Massimo DI MAIO
Cancer Research and Treatment 2017;49(3):834-845
PURPOSE: The purpose of this study was to evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials investigating the efficacy of targeted agents in the second-line treatment of metastatic colorectal cancer (mCRC). MATERIALS AND METHODS: A systematic search of literature pertaining to randomized phase II and III trials evaluating targeted agents as second-line treatments for mCRC was performed. The strength of the correlation between both PFS and ORR and OS was assessed based on the Pearson's correlation coefficient (R) and the coefficient of determination (R²). RESULTS: Twenty trials, including a total of 7,571 patients, met the search criteria. The median duration of post-progression survival (PPS) was 7.6 months. The median differences between experimental and control arms were 0.65 months (range, –2.4 to 3.4) for the median PFS and 0.7 months (range, –5.8 to 3.9) for the median OS. PFS and ORR showed moderate (R=0.734, R²=0.539, p < 0.001) and poor correlation (R=0.169, R²=0.029, p=0.476) with OS, respectively. No differences between anti-angiogenic agents and other drugs were evident. CONCLUSION: Targeted agents investigated in the second-line treatment of mCRC provided minimal PFS gains translating into modest OS improvements. Considering both the moderate correlation between PFS and OS and the short duration of PPS, the OS should remain the preferred primary endpoint for randomized clinical trials in the second-line treatment of mCRC.
Arm
;
Biomarkers*
;
Colorectal Neoplasms*
;
Disease-Free Survival
;
Humans
;
Molecular Targeted Therapy
;
Translating
7.Novel method of histopathological analysis after testicular sperm extraction in patients with nonobstructive and obstructive azoospermia.
Gianmartin CITO ; Maria Elisabetta COCCIA ; Rita PICONE ; Gabriella NESI ; Andrea COCCI ; Sara DABIZZI ; Giulio GARAFFA ; Rossella FUCCI ; Patrizia FALCONE ; Francesco BERTOCCI ; Raffaella SANTI ; Luciana CRISCUOLI ; Sergio SERNI ; Marco CARINI ; Alessandro NATALI
Clinical and Experimental Reproductive Medicine 2018;45(4):170-176
OBJECTIVE: To assess whether the “testicular pool” could be used for histological analysis and whether it gave more accurate information than the standard testicular biopsy. METHODS: Between January 2017 and March 2018, this single-center prospective study included 60 azoospermic men undergoing conventional bilateral testicular sperm extraction. Six samples were excised from each testicle and transferred to an embryologist. One additional biopsy was randomly taken from each testis for a histological analysis. After processing, the testicular pool was also sent for a histological analysis, which showed normal spermatogenesis (NS), hypospermatogenesis (HYPO), maturation arrest (MA), Sertoli cell-only syndrome (SCOS), and tubular atrophy (TA). RESULTS: Twenty of the 60 patients (33.3%) had obstructive azoospermia (OA), while the remaining 40 (66.6%) had nonobstructive azoospermia. Their mean age was 40.5 years. All patients with OA had previously undergone unsuccessful testicular fine-needle aspiration. Successful sperm retrieval (SSR) occurred in 93.3% of patients. Histological analysis of the testicular biopsy revealed NS in 12 patients (20%), HYPO and TA in 28 patients (46.6%), MA in eight patients (13.3%), and SCOS in 12 patients (20%). The testicular pool analysis showed NS in 12 patients (20%), HYPO and TA in 44 patients (73.3%), MA in four patients (6.6%), and SCOS in no patients. In four patients with MA (6.6% of the total sample) and 12 patients with SCOS (20% of the total sample) according to the standard testicular biopsy, the embryologist found SSR with cryopreservation. Overall, in 44 patients (73.3%), the testicular pool analysis confirmed the histological findings of the standard testicular biopsy. In the 16 cases (26.6%) with a discrepancy between the single-biopsy histological findings and SSR, the testicular pool analysis confirmed the embryological data on SSR. CONCLUSION: The testicular pool proved to be easily analyzable, practical, manageable, and more accurate for predicting sperm retrieval than standard testicular biopsy.
Atrophy
;
Azoospermia*
;
Biopsy
;
Biopsy, Fine-Needle
;
Cryopreservation
;
Humans
;
Infertility, Male
;
Male
;
Methods*
;
Oligospermia
;
Prospective Studies
;
Sertoli Cell-Only Syndrome
;
Sperm Retrieval
;
Spermatogenesis
;
Spermatozoa*
;
Testis